Your browser doesn't support javascript.
loading
Clinical effects and safety of terbutaline combined with budesonide atomized inhalation in the treatment of children with bronchiolitis obliterans / 中国基层医药
Chinese Journal of Primary Medicine and Pharmacy ; (12): 1525-1528, 2018.
Artigo em Chinês | WPRIM | ID: wpr-701933
ABSTRACT
Objective To investigate the clinical effects and safety of terbutaline combined with budesonide atomized inhalation in the treatment of children with bronchiolitis obliterans .Methods 140 cases of children with bronchiolitis obliterans from June 2015 to June 2017 were selected as research subjects , and they were randomly divided into control group and observation group according to the digital table ,with 70 cases in each group .The control group was given budesonide atomized inhalation alone ,and the observation group was given terbutaline combined with budesonide atomized inhalation .The clinical effects ,disappeared time of symptoms ,levels of IL-4 and INF-γbefore and after treatment and incidence rate of adverse effects in the two groups were compared .Results The excellent effective rate and total effective rate of the control group were 28.57%,78.57%,respectively,which were significantly lower than those of the observation group (44.29%,95.71%) (χ2 =9.73,8.60,all P<0.05).The disappeared time of symptoms of the observation group was significantly shorter than those of the control group ( t=2.67,3.15,2.20, 2.36,all P<0.05).The levels of IL-4 and INF-γafter treatment of the observation group were significantly higher than those of the control group and before treatment (t=2.44,2.71,3.07,3.66,2.94,3.26,all P<0.05).The incidence rates of adverse effects of the control group and the observation group were 8.57%,11.43%,respectively, there was no statistically significant difference between the two groups (χ2 =1.49,P>0.05).Conclusion Terbutaline combined with budesonide atomized inhalation in the treatment of children with bronchiolitis obliterans can efficiently control the disease progression ,shorten the clinical disease course ,regulate the levels of IL -4 and IFN-γand not aggravate the adverse drug reactions .

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Idioma: Chinês Revista: Chinese Journal of Primary Medicine and Pharmacy Ano de publicação: 2018 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Idioma: Chinês Revista: Chinese Journal of Primary Medicine and Pharmacy Ano de publicação: 2018 Tipo de documento: Artigo